The Future of Genus Patenting Strategies for Antibodies Post-Amgen

Zachary Silbersher

In 2023, the Supreme Court issued a decisive opinion that undermined the validity of broad functional genus claims for patents directed to biological antibodies. I published an article on IPWatchdog that examines numerous alternative patenting strategies for acquiring antibody claims that can survive enablement and written description challenges post-Amgen, with a focus on emerging data-driving approach involving paratope mapping with CDR-scanning technology. Go to IPWatchdog for full article.